Rhelion Life Sciences completed its acquisition of Filament Health in Q1 2027, enhancing its capabilities in pharmaceutical drug development and shifting focus to naturally derived psychedelic medicines, including its patented psilocybin drug candidate PEX010. The company reported $2.6 million in cash, $5 million in short-term investments, $0.186 million in revenue, and a net loss of $1.889 million for the quarter. Rhelion plans to advance PEX010 and explore other botanical drug candidates like IBEX011, derived from iboga. This acquisition positions Rhelion to expand clinical research supply and develop a differentiated life sciences platform in the psychedelic sector.
Sandisk and Kioxia announced plans to invest over $31 billion in their memory manufacturing facilities in Japan. This investment represents about 60% of what they have spent there over the past 25 years, signaling a major expansion in their productio...
Amazon reported strong Q2 results with AWS growth accelerating to 37% and advertising revenue growing 26%, signaling robust business momentum. The company’s cloud backlog reached $496 billion, and its AI and chip units surpassed $25 billion annualize...
Hyperliquid, a decentralized perpetual futures exchange, has reached an open interest of $13.3 billion, surpassing the combined open interest of the next nine decentralized exchanges. This milestone highlights Hyperliquid's dominant position in the o...
Public Service Enterprise Group (PSEG), a New Jersey-based utility with a $36 billion market cap and about 13,000 employees, has increased its dividend for 15 consecutive years. The company's 10-year dividend growth rate is 4.9%, reflecting steady bu...
XRP is expected to rally in September, defying the usual seasonal crypto market downturn. Historical data since 2018 shows XRP has averaged a 12.19% gain in September, outperforming Bitcoin's typical correction. This bullish outlook is supported by s...
